MedTrace Logo

Proxalutamide Treatment for COVID-19 Female Outpatients

NCT04853134 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2022-03-04

No results posted yet for this study

Summary

This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection

Conditions

  • Covid19
  • SARS-CoV Infection

Interventions

DRUG

Proxalutamide

200 mg q.d.

OTHER

Standard of Care

Standard of care as determined by the PI

Sponsors & Collaborators

  • Applied Biology, Inc.

    lead INDUSTRY

Principal Investigators

  • Flavio Cadegiani, MD · Corpometria Institute

  • Carlos Wambier, MD · Applied Biology, Inc.

  • Andy Goren, MD · Applied Biology, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2021-12-01
Completion
2021-12-01

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04853134 on ClinicalTrials.gov